image: A/Prof David Tan and Dr Natalie Ngoi of the National University Cancer Institute, Singapore (NCIS), are part of the team behind the LARA trial
Credit: National University Cancer Institute, Singapore (NCIS)
|
National University Cancer Institute, Singapore (NCIS) |
新加坡国立大学癌症中心 (国大癌症中心) |
|
National University Hospital (NUH) |
国立大学医院(国大医院) |
|
National Cancer Centre Singapore |
新加坡国立癌症中心 |
|
National University of Singapore (NUS) |
新加坡国立大学 |
|
Cancer Science Institute of Singapore at NUS (CSI Singapore) |
国大新加坡癌症科学研究所 |
|
NUS Saw Swee Hock School of Public Health |
国大苏瑞福公共卫生学院 |
|
NUS Yong Loo Lin School of Medicine |
国大杨潞龄医学院 |
|
Assoc Prof David Tan Senior Consultant Department of Haematology-Oncology, NCIS
Associate Professor Department of Medicine NUS Yong Loo Lin School of Medicine
Principal Investigator Cancer Science Institute of Singapore at NUS
|
陈邵平副教授 高级顾问医生 肿瘤血液科 国大癌症中心
副教授 内科系 国大杨潞龄医学院
主要研究员 国大新加坡癌症科学研究所 |
|
Dr Natalie Ngoi Consultant Department of Haematology-Oncology, NCIS |
魏燕丽医生 顾问医生 肿瘤血液科 国大癌症中心 |
Journal
The Lancet Oncology
Method of Research
Experimental study
Subject of Research
People
Article Title
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial
Article Publication Date
28-Feb-2026